While targeting Tregs holds promise for improving cancer treatment outcomes, it also carries potential risks. Depleting Tregs can lead to the breakdown of immune tolerance, resulting in autoimmune reactions and systemic inflammation. Therefore, it is crucial to develop targeted therapies that can selectively modulate Tregs within the TME without affecting their systemic functions.
